Related Experiment Videos
Secondary prevention after myocardial infarction with class III antiarrhythmic drugs
1Department of Cardiology, Postgraduate Medical School, Grochowski Hospital, Warsaw, Poland.
Insights
First-year mortality after myocardial infarction (MI) remains high. Low-dose amiodarone shows promise in reducing cardiac mortality post-MI, with studies indicating significant reductions and no serious side effects.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- First-year mortality after myocardial infarction (MI) is approximately 15%.
- Ventricular arrhythmias late after MI are a significant risk factor for sudden cardiac death.
- Previous antiarrhythmic drugs (Class I) have shown ineffectiveness or increased mortality risk.
Purpose of the Study:
- To evaluate the efficacy of Class III antiarrhythmic drugs, specifically amiodarone, in reducing post-myocardial infarction mortality.
- To assess the safety and effectiveness of low-dose amiodarone in patients following myocardial infarction.
Main Methods:
- Review of clinical trials investigating antiarrhythmic drug efficacy post-MI.
- Analysis of studies such as the Basel Antiarrhythmic Study of Infarct Survival (BASIS) and the Polish Amiodarone Study.
- Focus on low-dose amiodarone administration (200-400 mg/day).
Main Results:
- Beta blockers decrease first-year mortality by 26-36% but are not highly effective against ventricular ectopic beats.
- Early studies with sotalol showed a non-significant trend towards decreased mortality.
- The BASIS trial demonstrated a statistically significant reduction in total mortality with low-dose amiodarone.
- The Polish Amiodarone Study reported a 42% reduction in first-year cardiac mortality with low-dose amiodarone, with no serious side effects.
Conclusions:
- Low-dose amiodarone appears to be a promising therapeutic option for reducing mortality after myocardial infarction.
- Further ongoing trials are expected to provide more comprehensive data on amiodarone's impact on post-MI mortality.
- Amiodarone, at low doses, offers a potential strategy to mitigate sudden cardiac death risk in post-MI patients.
Abstract:
First-year mortality after myocardial infarction (MI) is high, amounting to 15%. It has been well documented that ventricular arrhythmias late after MI constitute a risk factor for sudden cardiac death. Consequently, several authors undertook attempts to decrease post-MI mortality with antiarrhythmic drugs. Unfortunately, the class I drugs most widely used in clinical practice proved to be ineffective or they even increased the risk of death, as occurred in the Cardiac Arrhythmia Suppression Trial (CAST). So far, only beta blockers, although not particularly effective in controlling ventricular ectopic beats, have been found to decrease first-year mortality after MI by 26-36%. Class III drugs appear to be promising in this clinical setting. Early study with sotalol showed a positive, although statistically nonsignificant, trend toward decreasing mortality. In a more recent trial with amiodarone (Basel Antiarrhythmic Study of Infarct Survival [BASIS]) done in Switzerland, total mortality was reduced (p < 0.05). It should be stressed that the drug was administered at a low dosage level (200 mg/day) to 98 patients and did not cause serious side effects. Similarly encouraging results have been provided by the Polish Amiodarone Study. Amiodarone given to 305 patients at a low dose (200-400 mg/day) reduced first-year cardiac mortality by 42% (p < 0.05). No serious side effects were noticed. Several ongoing trials should further substantiate the impact of this regimen on mortality after MI.